Actively Recruiting

Phase 3
Age: 18Years - 35Years
FEMALE
Healthy Volunteers
NCT06394999

Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

Led by Leiden University Medical Center · Updated on 2025-09-16

1186

Participants Needed

14

Research Sites

256 weeks

Total Duration

On this page

Sponsors

L

Leiden University Medical Center

Lead Sponsor

K

Karolinska Institutet

Collaborating Sponsor

AI-Summary

What this Trial Is About

Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. It is important to know how people experience that use of one tablet a week.

CONDITIONS

Official Title

Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

Who Can Participate

Age: 18Years - 35Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-35 at the moment of signing informed consent
  • For women 30 years or older, prior HPV or pap-test required
  • Understand and speak Dutch or English
  • Willing to use mifepristone as the only contraception method for 12 months
  • Able to take oral medication and follow the study protocol
  • Have unprotected vaginal heterosexual intercourse with a non-sterilized partner at least once a month
  • Body mass index (BMI) less than 35 kg/m2
  • Willing to fill in a daily diary on smartphone or computer and complete five online questionnaires
  • Able to attend scheduled visits and comply with the study protocol
  • Provide informed consent and permission to request medical data if complications or pregnancy occur
  • If not using hormonal contraceptives, have a menstrual cycle of 21-35 days
  • If previously using Depo-Provera, allow at least three cycles of 21-35 days after stopping
  • If using progesterone treatment, willing to use condoms temporarily
Not Eligible

You will not qualify if you...

  • Currently pregnant or breastfeeding
  • Desire to become pregnant within the next 12 months
  • Signs of current endometritis, incomplete abortion after miscarriage or induced abortion, or retained placental tissue after delivery
  • Undiagnosed post-coital or unscheduled bleeding (spotting allowed with hormonal contraceptives except for some methods)
  • Known subfertility or history of ectopic pregnancy unless followed by intra-uterine pregnancy, or severe endometriosis proven by laparoscopy
  • History of gastric reduction, gastric bypass, or use of weight-loss medicines
  • Previous or current liver disease or infection affecting the liver, or moderately abnormal liver enzymes at screening
  • Current or past cancer or ductal carcinoma in situ (DCIS)
  • Family history of endometrial cancer except for BRCA gene mutation
  • Known allergy to mifepristone
  • Use of non-dermal corticosteroids or drugs that interact with mifepristone
  • Participation in another investigational drug study unless principal investigators agree
  • Undiagnosed severe anemia or increased creatinine
  • Abnormal previous PAP smear without colposcopic evaluation or untreated high-grade lesions
  • High blood pressure with systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg
  • Abnormal vaginal ultrasound findings such as polyps, myomas, thickened endometrium, or hydrosalpinx
  • Previous participation in the WOMEN&More trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

Noordwest Ziekenhuisgroep

Alkmaar, Netherlands, 1815 JD

Actively Recruiting

2

Ziekenhuisgroep Twente

Almelo, Netherlands, 7609 PP

Not Yet Recruiting

3

Flevoziekenhuis

Almere Stad, Netherlands, 1315 RA

Not Yet Recruiting

4

Amsterdam Universitair Medische Centra

Amsterdam, Netherlands, 1105 AZ

Not Yet Recruiting

5

Medisch Spectrum Twente

Enschede, Netherlands, 7512 KZ

Actively Recruiting

6

Admiraal De Ruyter Ziekenhuis

Goes, Netherlands, 4462 RA

Actively Recruiting

7

Martini Ziekenhuis

Groningen, Netherlands, 9728 NZ

Actively Recruiting

8

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands, 8934 AD

Actively Recruiting

9

Leiden University Medical Center

Leiden, Netherlands, 2333 ZA

Actively Recruiting

10

Maastricht Universitair Medisch Centrum

Maastricht, Netherlands, 6229 HX

Not Yet Recruiting

11

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands, 6532 SZ

Not Yet Recruiting

12

Franciscus Gasthuis

Rotterdam, Netherlands, 3045 PM

Actively Recruiting

13

Diakonessenhuis

Utrecht, Netherlands, 3582 KE

Not Yet Recruiting

14

Maxima Medisch Centrum

Veldhoven, Netherlands, 5504 DB

Actively Recruiting

Loading map...

Research Team

R

Rebecca Gomperts, PhD

CONTACT

E

Elma Meershoek, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here